NHS adopts rapid genomic test that identifies brain tumours in hours

NHS England has started piloting a rapid genomic test that can classify brain tumours in roughly two hours, dramatically reducing the usual six-to-eight-week wait. The assay analyses DNA from tiny tumour samples with an Oxford Nanopore sequencer and software developed at the University of Nottingham, producing a molecular fingerprint that guides treatment. Patients such as 55-year-old Steve Palmer received a glioblastoma diagnosis while still on the operating table, allowing surgeons to adjust their approach in real time.

Experts like consultant neurosurgeon Stuart Smith and neuropathologist Simon Paine describe the method as transformative for surgical planning and for accessing targeted therapies or clinical trials. The initial rollout involves specialist centres in Nottingham, Birmingham, London and Newcastle, with plans to add sites in Bristol, Oxford, Leeds and Manchester. NHS officials view the test as a step toward routine rapid genomic diagnostics across the health service.